The Uromigos at ASCO GU 2023: Discussing KEYNOTE-057 With Andrea Necchi, MD

By The Uromigos - Last Updated: August 1, 2023

The Uromigos met with Andrea Necchi, MD at the 2023 ASCO GU Cancers Symposium to discuss results of the phase 2 KEYNOTE-057 study on the use of pembrolizumab monotherapy for patients with high-risk non-muscle-invasive bladder cancer who are unresponsive to bacillus Calmette–Guérin therapy.
Dr. Necchi is an Associate Professor at Università Vita-Salute San Raffaele, Head of Genitourinary Medical Oncology at Ospedale San Raffaele, and Vice President of the Global Society of Rare GU Tumors.

Post Tags:Uromigos-ASCO GUUromigos-Bladder Cancer